Matrixx Initiatives Inc. (MTXX)

[MC10459]

what's the deal here?

[scion]

The Court in charge of the case is the United States District Court for the District of Arizona (the “Court”) and the case is known as Siracusano v. Matrixx Initiatives, Inc., et al., Civ. No. 04-0886-PHX-NVW.

The entity that leads the Litigation, NECA-IBEW Pension Fund (the Decatur Plan) is called the Lead Plaintiff, and the parties it sued are called Defendants. Defendants in this case are Matrixx, Carl J. Johnson, William J. Hemelt, and Timothy L. Clarot.

NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION

If you purchased Matrixx Initiatives, Inc. (“Matrixx”) common stock or put or call options (collectively, “Matrixx Securities”) during the period between October 22, 2003 and February 6, 2004, inclusive (the “Class Period”), and are
not otherwise excluded from the Class, you could get a payment from a class action settlement.

A federal court authorized this Notice. This is not a solicitation from a lawyer.
[...]
More

http://ktmc.com/files/pdf_settled/notice_480.pdf

[locksflooring]

Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21)
Date : 01/20/2011 @ 4:10PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 8.47 -0.02 (-0.24%) @ 7:22AM


Matrixx Initiatives, Inc. Reports Fiscal 2011 Third Quarter Net Sales of $20.3 Million and Net Loss of $11.3 Million, or $(1.21)

Matrixx Initiatives Inc. (MM) (NASDAQ:MTXX)
Intraday Stock Chart
Today : Thursday 20 January 2011
Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal third quarter and nine months ended December 31, 2010.

For the third quarter ended December 31, 2010, the Company reported net sales of $20.3 million, or 29% below the $28.5 million in net sales for the comparable quarter last year. The Company reported a net loss for the quarter ended December 31, 2010 of $11.3 million, or $(1.21) per diluted share, compared to net income of $3.8 million, or $0.41 per diluted share, for the quarter ended December 31, 2009. The net loss includes $15.0 million of net costs associated with the settlement of the personal injury product liability claims ($15.5 million for the settlement less the $523,000 previously reserved) , $2.2 million to reserve for costs associated with the potential settlement of the economic injury claims, and approximately $1.8 million for merger-related expenses. The lower level of sales versus the quarter ended December 31, 2009 is primarily attributable to last year's high pre-season inventory purchases by retailers due to publicity of the H1N1 flu outbreak.

For the nine months ended December 31, 2010, the Company reported net sales of $44.8 million, and a net loss of $8.4 million, or $(0.91) per diluted share. This compares to net sales of $61.0 million, and a net loss of $(13.9) million, or $(1.51) per diluted share, for the nine months ended December 31, 2009. Results for the nine months ended December 31, 2009 included $2.0 million of sales of nasal Cold Remedy products, which were withdrawn from the market in June 2009, and charges of $32.9 million related to withdrawal of the products.

Bill Hemelt, President and Chief Executive Officer, said, "We began to see increases in consumer purchases of our products during the last half of our fiscal third quarter as new advertising commenced and the incidence of illness surpassed last year's illness level. Retailers continued to trim their inventory levels in comparison to last year; however, we believe retailers' inventory of our products has reached a point where they will increase purchases to offset the increased consumer takeaway. For the four weeks ended December 26, 2010, retail unit sales (three-outlet syndicated scanner data, not including Wal-Mart or club stores) of Zicam Cold Remedy oral delivery products increased approximately 30%, while the total cough/cold category increased approximately 5% compared to the prior year. We attribute the market share gains to increased and improved advertising and other marketing activities. For the full fiscal year ending March 31, 2011, we anticipate revenue increasing 3% to 5% above the $67.3 million achieved in fiscal 2010."

As previously disclosed, on December 13, 2010, the Company executed a settlement agreement associated with the bulk of the personal injury product liability claims and lawsuits. The settlement calls for the Company to pay $15.5 million to the claimants. The Company paid the first installment of $11.5 million into an escrow account and that amount is recorded as restricted cash on the Company's balance sheet until certain terms of the settlement are met. The remaining $4.0 million will be paid out over the next 20 months.

Results for the quarter ended December 31, 2010 include legal defense costs of approximately $2.2 million, which was reduced by $942,000 of insurance reimbursement, resulting in net legal defense expense of $1.3 million, compared to expense of $1.8 million in the quarter ended December 31, 2009. For the nine months ended December 31, 2010, product liability and regulatory legal defense costs were $7.0 million which was offset by $5.0 million of insurance reimbursement (which exhausted the insurance policy), compared to $4.7 million in the nine months ended December 31, 2009.

Matrixx Initiatives, Inc.

(Unaudited)


Three Months Ended Dec. 31,
Nine Months Ended Dec. 31,

($000s)
2010
2009
2010
2009

Net Sales
$ 20,289
$ 28,463
$ 44,807
$ 61,006

Cost of Sales
5,948
7,650
12,871
17,273

Gross Profit
14,341
20,813
31,936
43,733

Selling, General & Administrative
32,333
14,068
44,411
40,707

Research and Development
338
543
1,222
1,896

Goodwill Impairment
-
-
-
15,040

Asset Impairments
-
-
-
8,827

Income (Loss) from Operations
(18,330)
6,202
(13,697)
(22,737)

Total Other Income
5
33
28
119

Income (Loss) Before Tax
(18,325)
6,235
(13,669)
(22,618)

Income Taxes
(7,045)
2,409
(5,247)
(8,691)

Net Income (Loss)
$ (11,280)
$ 3,826
$ (8,422)
$ (13,927)


Net Income (Loss) per Diluted Share
$ (1.21)
$ 0.41
$ (0.91)
$ (1.51)

Average Shares Outstanding (mil)
9.3
9.2
9.3
9.2


Selected Balance Sheet Information


($000s)
Dec. 31, 2010
March 31, 2010
Dec. 31, 2009

Cash and Certificates of Deposit
$23,530
$30,219
$33,270

Accounts Receivable - Trade
$9,385
$5,386
$15,787

Inventory
$8,076
$6,167
$5,340

Restricted Cash
$11,500
-
-

Total Assets
$70,225
$61,465
$73,536

Current Liabilities
$26,927
$10,384
$12,247

Working Capital
$26,223
$44,355
$53,529

Total Debt
$0
$0
$0

Shareholders' Equity
$43,298
$51,082
$61,289



About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is an over-the-counter healthcare company that develops and markets Zicam® products. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Vice President of Finance & Accounting, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

Matrixx Initiatives, Inc. Forward-Looking Statement Disclaimer:

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "plan," "anticipate," and other similar statements of expectation identify forward-looking statements and include statements regarding: (i) our expectations of increased sales in the fourth quarter ending March 31, 2011; (ii) our expectations regarding reorders and consumer purchases of Zicam products; and (iii) our expectations regarding the settlement of legal issues. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include: (a) the severity and timing of the cold season; (b) the possibility that future sales of our products will not be as strong as expected; (c) the possibility that supply issues may impact future sales of our products; (d) the possibility that our products may face increased competition or negative publicity; (e) the potential impact of current and future product liability, advertising, and securities litigation; (f) regulatory issues or public relations challenges, including those associated with the FDA's June 2009 warning letter, which required the withdrawal of our nasal Cold Remedy products; (g) the possibility of delays or other difficulties in selling our products or in implementing new product improvements and introducing to the marketplace new products and brands; (h) the possibility that expenses, including legal expenses, reserves, and expenses associated with adverse litigation outcomes may exceed expected amounts; (i) the possibility of future product recalls; (j) increased competition from private label manufacturers; and (k) the possibility that adverse economic conditions may affect consumer demand. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Annual Report on Form 10-K filed on June 7, 2010, under the heading "Risk Factors," filed pursuant to the Securities Exchange Act of 1934. We do not undertake, and we specifically disclaim, any obligation to publicly update or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE Matrixx Initiatives, Inc.

[locksflooring]

Did you see the NEWS

[bsdaddy]

Sweet!

[locksflooring]

WoW Nice Day

[bsdaddy]

Rigrodsky & Long, P.A. Investigates Matrixx Initiatives Inc.

BuyoutLast update: 12/14/2010 10:13:00 AMWILMINGTON, Del., Dec 14, 2010 (BUSINESS WIRE) -- Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Matrixx Initiatives Inc. ("Matrixx Initiatives" or the "Company") (MTXX) concerning possible breaches of fiduciary duty and other violations of law related to the Company's entry into an agreement to be acquired and taken private by investment funds managed by H.I.G. Capital, LLC ("H.I.G.") in a cash transaction valued at approximately $75.2 million. Click here to learn how to join the action: . Under the proposed agreement, affiliates of H.I.G. will commence a tender offer to purchase for cash all of the outstanding shares of Matrixx Initiatives common stock, and the associated preferred stock purchase rights, at a price of $8.00 per share (the "Tender Offer"). The Tender Offer is expected to commence on December 22, 2010 and to expire on the 20th business day following and including the commencement date, unless extended in accordance with the terms of the merger agreement. If the Tender Offer is successfully completed, the parties will complete a second--step merger in which any remaining shares of Matrixx Initiatives would be converted into the right to receive the same price per share paid in the Tender Offer. The investigation concerns whether Matrixx Initiatives' board of directors failed to adequately shop the Company and obtain the best price possible for Matrixx Initiatives' shareholders before entering into the agreement with H.I.G. Indeed, according to Yahoo! Finance, at least one analyst has set a price target of $8.50 per share for Matrixx Initiatives stock. If you own the common stock of Matrixx Initiatives and purchased your shares before December 14, 2010, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware, by telephone at [phone], or by e-mail to [e-mail]. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.

[bsdaddy]

Matrixx Initiatives, Inc. to Be Acquired by H.I.G.


SCOTTSDALE, Ariz., Dec. 14, 2010 /PRNewswire-FirstCall/ -- Matrixx Initiatives, Inc. (Nasdaq: MTXX) ("Matrixx" or the "Company") today announced that it has entered into a definitive merger agreement to be acquired by investment funds managed by H.I.G. Capital, LLC, a leading global private investment firm.
Under the terms of the merger agreement, affiliates of H.I.G. will commence a tender offer to purchase for cash all of the outstanding shares of Matrixx common stock, and the associated preferred stock purchase rights, at a price of $8.00 per share, which represents a 56.3% premium to the Company's closing stock price on December 13, 2010, the last full trading day before today's announcement, for a total value of approximately $75.2 million.
The tender offer is expected to commence on December 22, 2010 and to expire on the 20th business day following and including the commencement date, unless extended in accordance with the terms of the merger agreement and the applicable rules and regulations of the Securities and Exchange Commission. If the tender offer is successfully completed, the parties will complete a second-step merger in which any remaining shares of Matrixx would be converted into the right to receive the same price per share paid in the tender offer.
Completion of the transaction is subject to, among other things, the satisfaction of the minimum tender condition of at least the majority of the Company's outstanding common shares on a fully diluted basis, expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and other customary closing conditions, but is not subject to any financing condition.
The Board of Directors of Matrixx has unanimously approved the merger agreement and the transactions contemplated by the merger agreement and has resolved to recommend that the Matrixx stockholders tender their shares in connection with the tender offer contemplated by the merger agreement.
Under the terms of the merger agreement, Matrixx may solicit acquisition proposals from third parties for a period from execution of the merger agreement until 11:59 p.m. on January 22, 2011. The Company's financial advisor, Sawaya Segalas LLC, will assist the Company's Board of Directors in connection with the solicitation. It is not anticipated that any developments will be disclosed with regard to this process unless the Company's Board of Directors makes a decision with respect to a potential superior proposal. There are no guarantees that this process will result in a superior proposal.
Sawaya Segalas & Co., LLC is acting as financial advisor to Matrixx. Sullivan & Cromwell LLP and Snell & Wilmer LLP are acting as legal counsel to Matrixx. Kirkland & Ellis LLP is acting as legal counsel to H.I.G.

[locksflooring]

Matrixx Initiatives, Inc. Reports Fiscal 2011 Second Quarter Net Sales of $21.3 Million and Net Income of $5.3 Million, or $0.57
Date : 10/25/2010 @ 4:05PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 5.19 0.0 (0.00%) @ 7:22AM


Matrixx Initiatives, Inc. Reports Fiscal 2011 Second Quarter Net Sales of $21.3 Million and Net Income of $5.3 Million, or $0.57
Matrixx Initiatives Inc. (MM) (NASDAQ:MTXX)
Intraday Stock Chart
Today : Monday 25 October 2010
Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal second quarter and six months ended September 30, 2010.

For the second quarter ended September 30, 2010, the Company reported net sales of $21.3 million, or 17% below the $25.6 million in net sales for the comparable quarter last year. The Company reported net income for the quarter of $5.3 million, or $0.57 per diluted share, compared to net income of $5.1 million, or $0.55 per diluted share, for the quarter ended September 30, 2009, primarily due to reduced net legal expense and the absence of a charge related to the Company's exit from the Canadian market in the prior year. The lower level of sales versus the quarter ended September 30, 2009 is primarily attributable to last year's high pre-season inventory purchases by retailers due to publicity of the H1N1 flu outbreak.

For the six months ended September 30, 2010, the Company reported net sales of $24.5 million, and net income of $2.9 million, or $0.31 per diluted share. This compares to net sales of $32.5 million, and a net loss of $(17.8) million, or $(1.93) per diluted share, for the six months ended September 30, 2009. Results for the six months ended September 30, 2009 included $2.0 million of sales of nasal Cold Remedy products, which were withdrawn from the market in June 2009 and charges of $32.9 million related to withdrawal of the products.

Bill Hemelt, President and Chief Executive Officer, said, "Sales in the fiscal second quarter were in line with the Company's plan. In the second quarter last year, retailers placed large pre-season orders in anticipation of increased levels of illness associated with H1N1. Those large pre-season buys reduced our sales in subsequent quarters. This year, the inventory level at retail going into the cold season is lower, and, as a result, we believe reorders during our fiscal third and fourth quarters will be higher. We expect our new advertising campaign, which will encompass television, print, and online media, will help increase consumer purchases of Zicam products. We believe our new creative will continue to differentiate our products from general symptom relief products and help increase consumer awareness. As part of these efforts, we recently launched a new web-based Zicam video featuring iconic television moms addressing cold myths. We encourage you to view this video at www.Zicam.com. Our new television advertising will begin airing in November at about the same time when illness levels grow."

As previously disclosed, the Company and its product liability insurer reached agreement that the insurer would transfer the full amount of a $5.0 million policy to the Company to offset legal expenses. The Company received the cash in August 2010. Results for the quarter ended September 30, 2010 include legal defense costs of $2.9 million, which were reduced by $1.9 million of the insurance reimbursement, resulting in net legal defense expense of $1.0 million, compared to legal defense expense of $2.4 million in the quarter ended September 30, 2009. For the six months ended September 30, 2010, legal defense costs were $4.8 million which were offset by $4.1 million of the insurance reimbursement. Legal expense for the six months ended September 30, 2009 was approximately $3.0 million. The Company expects the remaining $900,000 of insurance reimbursement will offset legal expense in the fiscal third quarter and does not expect to receive additional insurance reimbursements for legal expense. Operating expenses for the quarter declined from last year due to reduced net legal expense and a $1.6 million charge recorded in the quarter ended September 30, 2009, related to the Company's exit from the Canadian market.

For fiscal 2011, the Company anticipates revenue increasing 3% to 5% above the $67.3 million achieved in fiscal 2010. In addition, we anticipate increased marketing and legal expense will somewhat offset increased sales in the second half of the year and we expect to report net income for the full year between $2.0 and $3.0 million.

There will be a teleconference Tuesday, October 26, 2010 at 11:00 a.m. EDT to discuss fiscal 2011 second quarter financial results. To access the teleconference, please call [phone] (domestic) or [phone] (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations. A replay of the call will be available at [phone] (domestic) or [phone] (international), replay number 9008846 for 3 days following the call, and the web cast will be archived on the Company's website, http://www.matrixxinc.com, for 30 days.

Matrixx Initiatives, Inc.

(Unaudited)


Three Months Ended Sept. 30,
Six Months Ended Sept. 30,

($000s)
2010
2009
2010
2009

Net Sales
$ 21,311
$ 25,627
$ 24,518
$ 32,543

Cost of Sales
5,590
6,830
6,923
9,623

Gross Profit
15,721
18,797
17,595
22,920

Selling, General & Administrative
6,765
10,150
12,078
26,639

Research and Development
354
419
884
1,353

Goodwill Impairment
-
-
-
15,040

Asset Impairments
-
-
-
8,827

Income (Loss) from Operations
8,602
8,228
4,633
(28,939)

Total Other Income
7
38
23
85

Income (Loss) Before Tax
8,609
8,266
4,656
(28,854)

Income Taxes
3,318
3,188
1,798
(11,100)

Net Income (Loss)
$ 5,291
$ 5,078
$ 2,858
$ (17,754)


Net Income (Loss) per Diluted Share
$ 0.57
$ 0.55
$ 0.31
$ (1.93)

Average Shares Outstanding (mil)
9.3
9.2
9.3
9.2


Selected Balance Sheet Information


($000s)
Sept. 30, 2010
March 31, 2010
Sep. 30, 2009

Cash and Certificates of Deposit
$24,024
$30,219
$23,582

Accounts Receivable - Trade
$13,656
$5,386
$22,968

Inventory
$9,469
$6,167
$5,150

Total Assets
$63,676
$61,465
$72,699

Current Liabilities
$9,369
$10,384
$15,711

Working Capital
$48,436
$44,355
$48,803

Total Debt
$0
$0
$0

Shareholders' Equity
$54,307
$51,082
$56,988



About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is an over-the-counter healthcare company that develops and markets Zicam® products. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Vice President of Finance & Accounting, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

Matrixx Initiatives, Inc. Forward-Looking Statement Disclaimer:

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "plan," "anticipate," and other similar statements of expectation identify forward-looking statements and include statements regarding: (i) our revenue and net income expectations for the fiscal year ending March 31, 2011; (ii) our expectations regarding reorders and consumer purchases of Zicam products; (iii) our expectations regarding advertising and marketing of our products; and (iv) our expectations regarding legal expenses. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include: (a) the severity and timing of the cold season; (b) the possibility that future sales of our products will not be as strong as expected; (c) the possibility that supply issues may impact future sales of our products; (d) the possibility that our products may face increased competition or negative publicity; (e) the potential impact of current and future product liability, advertising, and securities litigation; (f) regulatory issues or public relations challenges, including those associated with the FDA's June 2009 warning letter, which required the withdrawal of our nasal Cold Remedy products; (g) the possibility of delays or other difficulties in selling our products or in implementing new product improvements and introducing to the marketplace new products and brands; (h) the possibility that expenses, including legal expenses, reserves, and expenses associated with adverse litigation outcomes may exceed expected amounts; (i) the possibility of future product recalls; (j) increased competition from private label manufacturers; and (k) the possibility that adverse economic conditions may affect consumer demand. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Annual Report on Form 10-K filed on June 7, 2010, under the heading "Risk Factors," filed pursuant to the Securities Exchange Act of 1934. We do not undertake, and we specifically disclaim, any obligation to publicly update or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE Matrixx Initiatives, Inc.

[locksflooring]

Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results
Date : 10/19/2010 @ 5:16PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 5.12 0.0 (0.00%) @ 3:50PM


Matrixx Initiatives, Inc. Sets Time for Discussion of Fiscal 2011 Second Quarter Financial Results
Matrixx Initiatives Inc. (MM) (NASDAQ:MTXX)
Intraday Stock Chart
Today : Tuesday 19 October 2010
Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company, announced today that financial results for the fiscal 2011 second quarter and six months ended September 30, 2010, will be released after the market closes on Monday, October 25, 2010. An earnings conference call will be held the following morning on Tuesday, October 26, 2010 at 11:00 AM ET.

To access the teleconference, please call [phone] (domestic) or [phone] (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations.

A replay of the call will be available at [phone] (domestic) or [phone] (international), replay code 9008846 for 3 days following the call, and the web cast will be archived on the company's website, http://www.matrixxinc.com, for 30 days.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Vice President of Finance & Accounting, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

SOURCE Matrixx Initiatives, Inc.

[deniseann]

Hi locksflooring.

Been a bit.

I am going to drop MTXX as a moderator, so you will be the only one on the mod list, and welcome to take mod over, if you should so desire.

Thanks for all the help.

denise.

[locksflooring]

Matrixx Initiatives, Inc. Reports Fiscal 2011 First Quarter Results
Date : 08/03/2010 @ 4:10PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 4.89 0.05 (1.03%) @ 7:22AM


Matrixx Initiatives, Inc. Reports Fiscal 2011 First Quarter Results
Matrixx Initiatives Inc. (MM) (NASDAQ:MTXX)
Intraday Stock Chart
Today : Tuesday 3 August 2010
Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal first quarter ended June 30, 2010.

For the fiscal first quarter ended June 30, 2010, the Company reported net sales of $3.2 million and a net loss of $2.4 million, or $(0.26) per diluted share. This compares to net sales of $6.9 million and a net loss of $22.8 million, or $(2.49) per diluted share, for the first quarter ended June 30, 2009. Last year's first quarter results included $2.0 million of sales of nasal Cold Remedy products, which were withdrawn from the market in June 2009, as well as charges of $32.9 million related to the recall and goodwill and asset impairments ($9.0 million for recall costs and $23.9 million of goodwill and asset impairments).

Bill Hemelt, President and Chief Executive Officer, said, "Sales in the fiscal first quarter are historically the lowest in the fiscal year. However, the quarter is a critical period for finalizing retail plans for the upcoming cold season and manufacturing new products to begin shipping in the fiscal second quarter. We began shipping our two new oral Cold Remedy products in July and significantly increased distribution of our Zicam Liqui-Loz Cold Remedy product for the upcoming cold season. We are pleased by customers' acceptance of these products. On average, our ten largest retail customers will have a net increase of oral Cold Remedy products on-shelf for this year's cold season. In addition, recent consumer consumption data comparing 4-week year-over-year trends following last year's withdrawal of our nasal Cold Remedy products, to the same period this year, shows growth of 5% for our oral Cold Remedy products and 7% for our allergy/congestion products. During our second quarter, we will be finalizing new oral Cold Remedy advertising, which we believe will help increase consumer awareness of our products' unique benefits. We are intent on growing sales of our nasal congestion products and are currently developing new advertising messaging for those products."

Mr. Hemelt continued, "Our overall litigation picture has become clearer and the process is moving quickly. The product lawsuits filed against the Company principally fall into two categories -- claims alleging our Zicam Cold Remedy nasal gel products caused loss of smell; and claims seeking compensation based on allegations that the Company misrepresented the safety and/or efficacy of our products. The majority of these cases fall into a multi-district litigation (MDL) process for which the judge has set a strict timetable for moving the cases forward. As previously reported, we are at the same time engaged in mediation with the paintiffs in an effort to settle the cases in order to avoid the costs and risks of litigation. However, if we are unable to resolve these matters in a manner that is in the Company's best interest, we will proceed with the litigation. Separately, during July 2010, the Company entered into settlement agreements with 46 potential claimants who, several years ago, had threatened to file lawsuits against the Company claiming that Zicam Cold Remedy nasal gel had caused a loss of smell. The Company denies the allegations but concluded for business reasons that it was in the Company's best interest to settle the claims. The settlement amounts were $5,000 or less per claimant and were paid from our litigation reserve."

"To avoid ongoing administrative costs, the Company and its product liability insurer reached agreement that the insurer would transfer the full amount of the $5.0 million policy to the Company. Based on this arrangement, the Company recorded $2.2 million, in the quarter ended June 30, 2010, as reimbursement of legal expenses for defending claims previously made against the policy. This resulted in a net credit of $0.3 million for product liability related legal expense ($1.9 million prior to insurance reimbursement) in the quarter ended June 30, 2010, which compares to legal expense of $0.6 million in the quarter ended June 30, 2009. The remaining $2.8 million to be received from the insurer will be applied against ongoing future legal expense. We expect to continue to incur legal expense of $1.3 million to $1.8 million per quarter before allocation of the remaining insurance proceeds."

For fiscal 2011, the Company anticipates revenue increasing 3% to 5% above the $67.3 million achieved in fiscal 2010. In addition, we expect to report net income between $2.0 and $3.0 million.

There will be a teleconference Wednesday, August 4, 2010 at 11:00 a.m. EDT to discuss first quarter fiscal 2011 financial results. To access the teleconference, please call [phone] (domestic) or [phone] (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations. A replay of the call will be available at [phone] (domestic) or [phone] (international), replay number 5413220 for 3 days following the call, and the web cast will be archived on the Company's website, http://www.matrixxinc.com, for 30 days.

Matrixx Initiatives, Inc.

(Unaudited)


Three Months Ended June 30,

($000s)
2010
2009

Net Sales
$ 3,208
$ 6,916

Cost of Sales
1,333
2,793

Gross Profit
1,875
4,123

Selling, General & Administrative
5,314
16,489

Research and Development
530
934

Goodwill Impairment
-
15,040

Asset Impairments
-
8,827

Loss from Operations
(3,969)
(37,167)

Total Other Income
16
47

Net Loss Before Tax
(3,953)
(37,120)

Income Tax Benefit
(1,520)
(14,288)

Net Loss
$ (2,433)
$ (22,832)


Net loss per Diluted Share
$ (0.26)
$ (2.49)

Average Shares Outstanding (mil)
9.3
9.2



Selected Balance Sheet Information


($000s)
June 30, 2010
March 31, 2010
June 30, 2009

Cash and Certificates of Deposit
$28,267
$30,219
$37,402

Accounts Receivable - Trade
$1,617
$5,386
$6,258

Inventory
$7,008
$6,167
$6,558

Total Assets
$59,118
$61,465
$72,446

Current Liabilities
$10,374
$10,384
$21,011

Working Capital
$42,479
$44,355
$43,090

Total Debt
$0
$0
$0

Shareholders' Equity
$48,744
$51,082
$51,435



About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is an over-the-counter healthcare company that develops and markets Zicam® products. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Vice President of Finance & Accounting, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

Matrixx Initiatives, Inc. Forward-Looking Statement Disclaimer:

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "plan," "anticipate," and other similar statements of expectation identify forward-looking statements and include statements regarding: (i) our revenue and net income expectations for the fiscal year ending March 31, 2011; (ii) our expectations regarding continued growth of Cold Remedy and congestion product sales and the resulting impact on our operations and financial results; (iii) our expectations regarding advertising and marketing of our products; and (iv) our expectations regarding legal expenses. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include: (a) the severity and timing of the cold season; (b) the possibility that future sales of our products will not be as strong as expected; (c) the possibility that supply issues may impact future sales of our products; (d) the possibility that our products may face increased competition or negative publicity; (e) the potential impact of current and future product liability, advertising, and securities litigation; (f) regulatory issues or public relations challenges, including those associated with the FDA's June 2009 warning letter, which required the withdrawal of our nasal Cold Remedy products; (g) the possibility of delays or other difficulties in selling our products or in implementing new product improvements and introducing to the marketplace new products and brands; (h) the possibility that expenses, including legal expenses, reserves, and expenses associated with adverse litigation outcomes may exceed expected amounts; (i) the possibility of future product recalls; (j) increased competition from private label manufacturers; and (k) the possibility that adverse economic conditions may affect consumer demand. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Annual Report on Form 10-K filed on June 7, 2010, under the heading "Risk Factors," filed pursuant to the Securities Exchange Act of 1934. We do not undertake, and we specifically disclaim, any obligation to publicly update or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE Matrixx Initiatives, Inc.

[MinnieM]

No kidding...

Try some daytrading... it's far from quiet. ;) I have a few other that all I do is daytrade them. Keeps me awake! ;)

[deniseann]

Still pretty quiet.

[MinnieM]

Hey girl... seems to be quiet over here. ;)

Have a great weekend. ;)

[deniseann]

Just checking in.

[locksflooring]

Matrixx Initiatives, Inc. Names William J. Barba Vice President of Finance and Accounting, and Treasurer
Date : 05/19/2010 @ 12:59PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 4.51 -0.08 (-1.74%) @ 7:22AM


Matrixx Initiatives, Inc. Names William J. Barba Vice President of Finance and Accounting, and Treasurer

Matrixx Initiatives, Inc. Names William J. Barba Vice President of Finance and Accounting, and Treasurer

PR Newswire

SCOTTSDALE, Ariz., May 19

SCOTTSDALE, Ariz., May 19 /PRNewswire-FirstCall/ --

Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets Zicam® products, today announced that Matrixx's Board of Directors has named William J. Barba as Vice President of Finance and Accounting, and Treasurer effective May 6, 2010.

Mr. Barba served as the Company's Treasurer and Director of Planning, since July 2007. Bill, 38, joined the Company in February 2004 in a finance and investor relations role. He assumed additional responsibilities as Director of Planning and Administration in 2006. Prior to joining Matrixx, he held a variety of financial management positions with Mesa Air Group, Honeywell Intellectual Properties, Avnet, and MicroAge.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, VP of Finance & Accounting, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

SOURCE Matrixx Initiatives, Inc.

[deniseann]

Agree... The recent bio mkt has really been getting slapped around...

Cute dogs Karen.

[MinnieM]

That teleconference didn't seem to help it.

[deniseann]

Wow! something knocks the wind out of the sails here this morning.

[deniseann]

Hi Karin. thanks for the update.

[MinnieM]

Teleconference Tuesday, May 11, 2010 at 11:00 a.m. EDT to discuss fourth quarter and fiscal 2010 financial results.

To access the teleconference, please call [phone] (domestic) or [phone] (international).

To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations.

A replay of the call will be available at [phone] (domestic) or [phone] (international), replay number 69901813 for 3 days following the call, and the web cast will be archived on the Company's website, http://www.matrixxinc.com, for 30 days.

[locksflooring]

Matrixx Initiatives, Inc. Reports Fiscal 2010 Fourth Quarter and Full-Year Results
Date : 05/10/2010 @ 4:01PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 4.97 0.18 (3.76%) @ 7:22AM


Matrixx Initiatives, Inc. Reports Fiscal 2010 Fourth Quarter and Full-Year Results

Matrixx Initiatives, Inc. Reports Fiscal 2010 Fourth Quarter and Full-Year Results

PR Newswire

SCOTTSDALE, Ariz., May 10

SCOTTSDALE, Ariz., May 10 /PRNewswire-FirstCall/ --

Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company that develops and markets Zicam® products that provide consumers with "better ways to get better®," today announced financial results for its fourth quarter and fiscal year ended March 31, 2010.

Fiscal 2010 Financial Results

For the fiscal year ended March 31, 2010, net sales were approximately $67.3 million, compared to net sales of $111.6 million for the fiscal year ended March 31, 2009. The Company incurred a net loss of approximately $23.6 million, or $(2.56) per diluted share, compared to net income of approximately $13.9 million, or $1.46 per diluted share, for fiscal 2009. Sales and operating results were significantly impacted by the recall of our nasal Cold Remedy products in June of 2009 (nasal Cold Remedy products accounted for approximately 40%, or $42.5 million of fiscal 2009 sales). Partially offsetting the nasal Cold Remedy revenue loss was a 22% increase in sales of oral Cold Remedy products. Product liability and recall-related legal expense increased to $6.2 million in fiscal 2010, compared to $2.5 million in fiscal 2009. For fiscal 2010, the Company incurred a loss from operations of $38.3 million which includes recall-related charges and asset impairments of $33.1 million. Income from operations in fiscal 2009 was $22.3 million and included $2.0 million for recall-related charges. Excluding the recall-related charges and asset impairments described above, the fiscal 2010 loss from operations was $5.2 million as compared to income from operations of $24.3 million in fiscal 2009.

Fourth Quarter Financial Results

For the fourth quarter ended March 31, 2010, the Company reported net sales of $6.3 million, versus net sales of $30.8 million in the quarter ended March 31, 2009. The Company incurred a net loss of approximately $9.6 million, or $(1.04) per diluted share, compared to net income of approximately $3.1 million, or $0.33 per diluted share, in the prior year's fourth quarter. Due to the publicity associated with H1N1 flu, retailers increased early season buys and carried elevated levels of inventory early in the cold season, which adversely impacted reorders in the fourth quarter of fiscal 2010. During the fourth quarter ended March 31, 2010, the Company recorded $10.9 million for marketing and advertising activities to continue to spur consumption during the end of the cold season.

Brand and Operating Highlights

Bill Hemelt, President and Chief Executive Operating Officer, said, "Fiscal 2010 was the single most challenging year for the Company. We navigated a recall of our two nasal Cold Remedy products and reset plans for our Zicam brand to achieve growth in the future. During the cold season we focused our advertising message to consumers around oral Cold Remedy products and realized growth in our oral Cold Remedy franchise. For the 52 weeks ended March 21, 2010, retail unit sales (three-outlet syndicated scanner data, not including Wal-Mart or club stores) of oral Zicam Cold Remedy products increased 12%, while the total cough/cold category unit sales were flat compared to the prior year. Despite facing increased store brand competition, we believe we can continue to grow our core Zicam business, which includes oral Cold Remedy and Allergy/Sinus products. In order to differentiate and promote the growth of our products, we will continue to refresh our consumer messaging and introduce new products." Additional fiscal fourth quarter and full-year 2010 metrics and highlights include:

Introduced two new and unique oral Cold Remedy products for the 2009/2010 cold season (Zicam Cold Remedy Zavors and Zicam Cold Remedy Liqui-Loz)Achieved average gross margin of 69% for fiscal 2010Ended the fiscal year with $30.2 million of cash and certificates of depositExecuted the new "Zicam = I Can" advertising programInvested 38% of sales in advertising and brand building activities to promote Zicam oral Cold Remedy products in light of the nasal products recallOur mix of core business net sales in fiscal 2010 was 66% oral Cold Remedy products and 26% allergy/sinus products, versus 33% and 20%, respectively, in fiscal 2009Oral Cold Remedy unit sales increased 28%Mr. Hemelt continued, "In fiscal 2011, the Company will focus on growing sales in our core Cold Remedy and Allergy/Sinus franchise and offsetting declines in our non-core product classes. For fiscal 2011, the Company anticipates revenue increasing 3% to 5% above the $67.3 million achieved in fiscal 2010. We anticipate expense for litigation will be between $1.3 million and $1.8 million per quarter in fiscal 2011. In addition, we expect to be cash flow positive and report net income between $2.0 and $3.0 million."

There will be a teleconference Tuesday, May 11, 2010 at 11:00 a.m. EDT to discuss fourth quarter and fiscal 2010 financial results. To access the teleconference, please call [phone] (domestic) or [phone] (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations. A replay of the call will be available at [phone] (domestic) or [phone] (international), replay number 69901813 for 3 days following the call, and the web cast will be archived on the Company's website, http://www.matrixxinc.com, for 30 days.

Matrixx Initiatives, Inc.

(Unaudited)

Three months ended March 31,

Twelve months ended March 31,

(In Thousands Except Per Share Amounts)

2010

2009

2010

2009

Net Sales

$ 6,311

$ 30,788

$ 67,317

$ 111,630

Cost of Sales

3,412

8,098

20,685

32,876

Gross Profit

2,899

22,690

46,632

78,754

Selling, General &

Administrative

17,970

17,037

58,677

53,205

Research and

Development

499

684

2,396

3,235

Asset Impairments

-

-

23,867

-

Income (Loss) from

Operations

(15,570)

4,969

(38,308)

22,314

Total Other Income

27

47

147

287

Net Income (Loss)

Before Tax

(15,543)

5,016

(38,161)

22,601

Income Tax Expense

(5,895)

1,879

(14,585)

8,737

Net Income

$ (9,648)

$ 3,137

$ (23,576)

$ 13,864

Net Income (Loss) per

Diluted Share

$ (1.04)

$ 0.33

$ (2.56)

$ 1.46

Average Shares Outstanding

(mil)

9.3

9.4

9.2

9.5

Selected Balance Sheet Information

($000s)

March 31, 2010

March 31, 2009

March 31, 2008

Cash and Certificates of Deposit

$30,219

$40,015

$27,933

Accounts Receivable - Trade

$5,386

$14,769

$12,052

Inventory

$6,167

$7,740

$11,530

Total Assets

$61,465

$91,360

$78,149

Current Liabilities

$10,384

$15,477

$10,574

Working Capital

$44,355

$52,075

$44,612

Total Debt

$0

$0

$0

Shareholders' Equity

$51,082

$73,077

$65,552

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Treasurer, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

Matrixx Initiatives, Inc. Forward-Looking Statement Disclaimer:

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "plan," "anticipate," and other similar statements of expectation identify forward-looking statements and include statements regarding: (i) our revenue and net income (loss) expectations for the fiscal year ending March 31, 2011; (ii) our expectations regarding continued growth of Cold Remedy product sales and the resulting impact on our operations and financial results; (iii) our expectations regarding advertising and marketing of our products; (iv) our expectations regarding legal expenses; (v) our expectations of being cash flow positive in fiscal 2011. These forward-looking statements are based on the Company's current expectations and are subject to a number of risks and uncertainties, many of which cannot be predicted or quantified and are beyond the Company's control. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. Factors that could cause actual results to differ materially from the Company's expectations include: (a) the severity and timing of the cold season; (b) the possibility that future sales of our products will not be as strong as expected; (c) the possibility that supply issues may impact future sales of our products; (d) the possibility that our products may face increased competition or negative publicity; (e) the potential impact of current and future product liability, advertising, and securities litigation; (f) regulatory issues or public relations challenges, including those associated with the FDA's June 2009 warning letter, which required the withdrawal of our nasal Cold Remedy products; (g) the possibility of delays or other difficulties in selling our products or in implementing new product improvements and introducing to the marketplace new products and brands; (h) the possibility that expenses, including legal expenses, product reserves, and expenses associated with adverse litigation outcomes or the product withdrawal associated with the FDA's warning letter, may exceed expected amounts; (i) the possibility of future product recalls; (j) increased competition from private label manufacturers; and (k) the possibility that adverse economic conditions may affect consumer demand. Other factors that could cause actual results to differ materially from the Company's expectations are described in the Company's Annual Report on Form 10-K filed on June 8, 2009, under the heading "Risk Factors," filed pursuant to the Securities Exchange Act of 1934. We do not undertake, and we specifically disclaim, any obligation to publicly update or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE Matrixx Initiatives, Inc.

[locksflooring]

Matrixx Initiatives, Inc. Sets Time for Discussion of Fourth Quarter and Fiscal 2010 Financial Results
Date : 05/04/2010 @ 2:38PM
Source : PR Newswire
Stock : Matrixx Initiatives Inc. (MM) (MTXX)
Quote : 5.09 -0.07 (-1.36%) @ 7:22AM


Matrixx Initiatives, Inc. Sets Time for Discussion of Fourth Quarter and Fiscal 2010 Financial Results

Matrixx Initiatives, Inc. Sets Time for Discussion of Fourth Quarter and Fiscal 2010 Financial Results

PR Newswire

SCOTTSDALE, Ariz., May 4

SCOTTSDALE, Ariz., May 4 /PRNewswire-FirstCall/ --

Matrixx Initiatives, Inc. (Nasdaq: MTXX), an over-the-counter healthcare company, announced today that financial results for the fiscal 2010 fourth quarter and year ended March 31, 2010, will be released after the market closes on Monday, May 10, 2010. An earnings conference call will be held the following morning on Tuesday, May 11, 2010 at 11:00 AM ET.

To access the teleconference, please call [phone] (domestic) or [phone] (international). To listen to the teleconference via the Internet, go to http://www.matrixxinc.com and click on Events & Presentations.

A replay of the call will be available at [phone] (domestic) or [phone] (international), replay code 69901813 for 3 days following the call, and the web cast will be archived on the company's website, http://www.matrixxinc.com, for 30 days.

About Matrixx Initiatives, Inc.

Matrixx Initiatives, Inc. is engaged in the development and marketing of over-the-counter healthcare products that utilize innovative drug delivery systems. Zicam, LLC, its wholly-owned subsidiary, markets and sells Zicam® products in the cough and cold category. The Company markets a full line of Zicam brand pharmaceuticals, including Zicam Cold Remedy in multiple oral delivery forms; Zicam Allergy and Congestion Relief products; as well as Zicam Cough and Zicam Multi-Symptom relief items. For more information regarding Matrixx products, go to www.Zicam.com. To find out more about Matrixx Initiatives, Inc. (Nasdaq: MTXX), visit our website at www.matrixxinc.com. For additional information, contact William Hemelt, President and Chief Executive Officer, 602-385-8888, or Bill Barba, Treasurer, 602-385-8881. Matrixx is located at 8515 E. Anderson Dr., Scottsdale, Arizona 85255.

SOURCE Matrixx Initiatives, Inc.

[locksflooring]

Looks like no one posted the 8k
Date : 04/14/2010 @ 4:45PM
Source : Edgar (US Regulatory)
Stock : (MTXX)
Quote : 5.27 -0.02 (-0.38%) @ 7:22AM


- Current report filing (8-K)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) April 14, 2010 & nbsp;
MATRIXX INITIATIVES, INC.
(Exact Name of Registrant as Specified in Its Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)


001-31404 87-0482806

(Commission File Number) (IRS Employer Identification No.)



8515 E. Anderson Drive, Scottsdale, Arizona 85255

(Address of Principal Executive Offices) (Zip Code)

[phone]
(Registrant’s Telephone Number, Including Area Code)
NONE
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))






--------------------------------------------------------------------------------





Item 2.02. Results of Operations and Financial Condition.

Matrixx Initiatives, Inc. has updated its fiscal 2010 revenue guidance. Matrixx now expects fiscal 2010 revenue to be in the $67 million to $68 million range. Previously, Matrixx expected fiscal 2010 revenue to be in the $68 million to $72 million range. In addition, as previously reported, the Company expects to report a sizable loss for the fiscal fourth quarter. The Company anticipates reporting fourth quarter and full-year fiscal 2010 results after the market closes on May 10, 2010.
The information being furnished pursuant to this Item 2.02 of this report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
2



--------------------------------------------------------------------------------




SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MATRIXX INITIATIVES, INC.
(Registrant)

/s/ William J. Hemelt
William J. Hemelt
President and Chief Executive Officer


Date: April 14, 2010

[deniseann]

checking in tap tap tap...

[deniseann]

Staying pretty steady in the 5's again

[MinnieM]

They don't have much volume either.

[deniseann]

Pretty much a holding pattern here lately.

[deniseann]

Thanks for the heads up tim.

Fridays are generally pretty busy for me, but will look, first chance. Again, great to have you on the board.

This will eventually work just fine.

denise.

[AUminer]

Thanks for The Share Structure, Deniseann. Real Good Looking Numbers. With Such a low O/S and Float this could Really Fly with the Right Moves and News.

Two others that are Hot right now which I would suggest are SPKL AND GRDO.

Also Check out "Pennyexpert News Picks" Board. It's new, But dedicated solely to Breaking and Very Recent News. I am an ass mod and You can get to it Quickly at my Profile.

Penny called that HCKI meteoric rise yesterday like ~8 am. (Unfortunately I was asleep after a Fun Nite). It would have been a Good Get In and Get Out Quick with a little "Play Money". (One should be Very Very Cautious on something being "Played that Hard") Don't Know if Your into that----But 6700% would have been nice!!!

Best Wishes with All Step by Step, Patiently Tim

[deniseann]

Authorized shares
30 million
Shares Float
9,030,254
Total Shares Outstanding
9,455,620
% Owned by Insiders
4.50 %
% Owned by Institutions
65.60 %
Market Cap.
$46,521,650

[deniseann]

Thanks AUminer, and welcome to the board.. It's been on the busy side here this morning (i still have to work). But i think you're right in you're assessment of mtxx.

It was running up around $19/share mid year, until the complaints to the fda came out about 2 of the 19 Zicam products, and it was sent spiraling down to about $5.

It's a solid company, and my gamble is somewhere along the line, it's going to head back. kind of in the tradition of the old investment stocks.

On the other side of the coin, as you so diligently noted, the mkts over all are not the same, and can't treated the same, as even a year and a half ago...

It's really pretty amazing alright.

denise.

[MinnieM]

Thanks...I'm unfamiliar with that site, but, will check it out. ;)





"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

[deniseann]

Hi karen...

As far as I know, this is accurate.

http://shortsqueeze.com/?symbol=mtxx&submit=Short+Quote%99

denise

[MinnieM]

Thanks...I like keeping them fairly simple, but, with key information. This one is missing share structure. Do you happen to have it? If not, I'll just look for it later this week. But, glad you like it so far. ;)

In Reply To 'deniseann'

Way cool job on the ibox karin... Just love it.

"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

[deniseann]

Way cool job on the ibox karin... Just love it.

[MinnieM]

I did a bit more tinkering in the box this evening. ;)





"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

[AUminer]

Most Mind-Provoking Siggy that I have Ever Seen Deniseann.

It Actually Strikes Right at The Heart of Most of Our Problems. Maybe it will Open Some Hearts as Well as Minds! (Actually it if Only Opens One it is Worth it)

[AUminer]

Nice to see You're so Involved with MTXX!!!! I Think that it is at the Least Solid Money and it has Lots of Potential. The Earnings have been up and down, But so has the PPS---Could be real Good with News. I'll be Sure to Keep a Sharp Eye on it at Bio-Med Reports.

That being Said; it is a TUFF MARKET!!!! EBAY should have flown today and didn't. The Big Investors are Unsure and are Holding Back until We get Some Direction---The State of The Union Tommorow Night might Provide Some Guidance---I Sure Hope So!!!!

[deniseann]

Nice graph on the ibox Karin.

[deniseann]

You're welcome & welcome to the board.

denise.

[locksflooring]

Thanks for the Add Denise!

[MinnieM]

MTXX weekly and daily chart











"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

[MinnieM]

Matrixx Initiatives, Inc. Reports Fiscal 2010 Third Quarter Sales of $28.5 Million and Net Income of $3.8 Million
http://www.prnewswire.com/news-releases/matrixx-initiatives-inc-reports-fiscal-2010-third-quarter-sales-of-285-million-and-net-income-of-38-million-82625757.html







"Be kinder than necessary, for everyone you meet is fighting some kind of battle."

[deniseann]

Kind of a short lived bounce, but nice to see mtxxx is still staying above $5.00

[deniseann]

Volume trading at 690% above average today.

[deniseann]

http://shortsqueeze.com/?symbol=mtxx&submit=Short+Quote%99

[deniseann]

Nice bounce after news of financial results, 3rd qtr, 2010, ending 12-31-09.

1-26-10, 4.56 to 5.25

denise.

[deniseann]

Still trying to creep along.